

Market Announcement

27 April 2026

Syntara Limited (ASX: SNT) – Trading Halt

Trading in the securities of Syntara Limited ('SNT') will be halted at the request of SNT, pending the release of an announcement by SNT.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 29 April 2026; or
- the release of the announcement to the market.

SNT's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

27 April 2026

ASX Compliance Pty Limited
39 Martin Place
Sydney NSW 2000

Syntara Limited (ASX: SNT) – Request for trading halt

Pursuant to ASX Listing Rule 17.1, Syntara Limited (Company) requests an immediate trading halt in respect of its ordinary shares (ASX: SNT).

For the purposes of Listing Rule 17.1, the Company provides the following information:

- a) The trading halt is requested pending an announcement by the Company in relation to correspondence from the U.S. Food and Drug Administration (**FDA**) following their review of a proposed clinical development pathway, and specifically a Phase 2b trial protocol, for the Company's lead asset Amsulostat.
- b) The Company requests that the trading halt remains in place until the earlier of commencement of trading on Wednesday, 29 April 2026 and the time at which the Company makes an announcement to the market in relation to the FDA correspondence referred to above.
- c) The Company confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely
Syntara Limited



Timothy Luscombe
Chief Financial Officer / Company Secretary

Authorised for release by the Board of Syntara Limited.

For personal use only